Company profile
NOVAVAX INC
NASDAQ:NVAXBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| MATRIX-M1 ADJUVANT | phase3 | — | 5 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (47)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02296463 | phase1 | completed | 2014-11-01 | 2015-09-01 | Novavax | A Phase I Randomized, Observer-Blinded, Dose-Ranging Study in Healthy Subjects 24 to <72 Months of Age |
| NCT06409663 | phase3 | completed | 2024-10-14 | 2024-10-15 | Novavax | A Strain Change Study for SARS-CoV-2 rS Vaccines |
| NCT04533399 | phase2 | completed | 2020-08-17 | 2021-12-07 | Novavax | A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults |
| NCT04583995 | phase3 | completed | 2020-09-28 | 2022-03-29 | Novavax | A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom |
| NCT02624947 | phase3 | completed | 2015-12-01 | 2018-12-28 | Novavax | A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization |
FDA applications (0)
No records yet.